Torrent Pharma currently has a strong fundamental setup

1. JB Chemicals merger — major structural trigger The JB Chemicals amalgamation became effective in July 2026. The combination substantially increases Torrent's India franchise and creates cost synergies. Management has raised its first-year JB cost-synergy expectation to more than ₹100 crore, above the earlier ₹90 crore target. 2. Strong India business India revenue grew 19%, significantly ahead of the Indian pharma market's ~12% growth. Torrent also became the market leader in cardiac therapies. 3. Semaglutide opportunity Torrent has launched Sembolic and Semalix, covering injectable and oral semaglutide for diabetes and obesity. Its semaglutide portfolio already achieved about 36% market share during Q1 FY27. This could become a meaningful long-term growth driver as India's obesity/diabetes treatment market expands. 4. International recovery US revenue increased 36% to ₹418 crore, helped by new launches and certain one-time opportunities, while Brazil grew 27%. Germany was weaker at +3% because of supplier disruptions and lower tender offtake. 5. Manufacturing/regulatory position Torrent's Bileshwarpura oncology facility received a zero-observation USFDA inspection in April 2026, which is a positive regulatory signal.